| 摘要: |
| ［摘要］ 目的 评价瑞替普酶对≥75岁ST段抬高心肌梗死(STEMI)溶栓治疗的疗效及安全性。方法 将入住博白县人民医院的STEMI并行溶栓的65例患者随机分为溶栓治疗组32例及对照组33例，两组均给予基础药物治疗，溶栓组增加减半剂量瑞替普酶溶栓治疗。观察并比较两组患者冠脉再通率、心梗1个月内主要心血管事件(MACE)发生率以及出血并发症发生率情况。结果 溶栓治疗组冠脉再通率为68.8%，高于对照组的15.2%（P<0.01），溶栓治疗组心肌梗死后1个月内病死率3.1%，低于对照组的24.2%，两组比较差异有统计学意义(P<0.05)。心衰、心源性休克以及缺血再发生率两组比较差异无统计学意义(P>0.05)。溶栓治疗组轻度出血发生率28.1%，高于对照组的6.1%(P<0.05)。两组患者均无中度及严重出血病例。结论 高龄STEMI患者采用减半量瑞替普酶进行溶栓治疗安全、有效。 |
| 关键词: 心肌梗死 瑞替普酶 老年人 |
| DOI：10.3969/j.issn.1674-3806.2015.07.05 |
| 分类号:R 542.2+2 |
| 基金项目:玉林市科学研究与技术开发计划项目（编号：玉科计字2015005001） |
|
| Efficacy and safety of half-dose reteplase as thrombolytics on more than 75-year-old patients with acute myocardial infarction |
|
CHEN Heng, GAN Jian-ting, ZHANG Hua-guang, et al.
|
|
Department of Cardiovascular, the People′s Hospital of Bobai County, Guangxi 537000, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the efficacy and safety of half-dose reteplase as thrombolytics on more than 75-year-old patients with ST-segment elevation myocardial infarction(STEMI).Methods 65 patients more than 75-year-old with STEMI were randomly divided into the observation group(n=32) and the control group(n=33). Both groups were treated with the primary medication, and the observation group received additional half-dose reteplase. The coronary artery recanalization rate and the occurrence of major adverse cardiovascular events(MACE), bleeding complications and thrombocytopenia were compared between the two groups.Results The coronary artery recanalization rate in the observation group was significantly higher than that in the control group(68.8% vs 15.2%,P<0.01). The death rate in the observation group was significantly lower than that in the control group(3.1% vs 24.2%,P<0.05). There were no significant differences in the incidences of heart failure, cardiogenic shock and ischemia between the two groups(P>0.05 ). The incidence of mild bleeding complication in the observation group was higher than that in the control group(28.1% vs 6.1%,P<0.05). There were no moderate to severe bleeding complications in the two groups.Conclusion Half dose of reteplase as thrombolytics is effective and safe for more than 75-year-old patients with STEMI. |
| Key words: Myocardial infarction Reteplase Aged |
